AC 면역 SA
DE ˙ DB ˙ CH0329023102
€1.98 ↓ -0.06 (-3.18%)
2026-06-04
주가
SecurityDE:IMR / AC Immune SA
InstitutionUBS Group AG
Latest Disclosed Ownership101,629 shares
Latest Disclosed Value $ 279,480
UBS Group AG reports 47.71% decrease in ownership of IMR / AC Immune SA

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 101,629 shares of AC Immune SA (DE:IMR) valued at $220,535 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 194,349 shares of AC Immune SA. This represents a change in shares of -47.71% during the quarter. The current value of the position is $201,225 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F AC IMMUNE SHS H00263105 101,629 -92,720 -47.71 279 -54.26 0.0000
2026-01-29 2025-12-31 13F AC IMMUNE SHS H00263105 194,349 177,925 1,083.32 610 1,197.87 0.0000
2025-11-13 2025-09-30 13F AC IMMUNE SHS H00263105 16,424 8,957 119.95 47 213.33 0.0000
2025-08-14 2025-06-30 13F AC IMMUNE SHS H00263105 7,467 -9,221 -55.26 15 -51.61 0.0000
2025-05-13 2025-03-31 13F AC IMMUNE SHS H00263105 16,688 -32,990 -66.41 31 -76.87 0.0000
2025-02-14 2024-12-31 13F AC IMMUNE SHS H00263105 49,678 35,050 239.61 134 143.64 0.0000
2024-11-14 2024-09-30 13F AC IMMUNE SHS H00263105 14,628 -1,512 -9.37 55 -14.06 0.0000
2024-08-14 2024-06-30 13F AC IMMUNE SHS H00263105 16,140 -7,525 -31.80 64 -8.57 0.0000
2024-05-13 2024-03-31 13F AC IMMUNE SHS H00263105 23,665 -21,335 -47.41 70 -68.89 0.0000
2024-02-09 2023-12-31 13F AC IMMUNE SHS H00263105 45,000 2,026 4.71 225 84.43 0.0001
2023-11-09 2023-09-30 13F AC IMMUNE SHS H00263105 42,974 100 0.23 122 -3.17 0.0000
2023-08-11 2023-06-30 13F AC IMMUNE SHS H00263105 42,874 0 0.00 127 26.00 0.0000
2023-05-12 2023-03-31 13F AC IMMUNE SHS H00263105 42,874 0 0.00 100 14.94 0.0000
2023-02-08 2022-12-31 13F AC IMMUNE SHS H00263105 42,874 -12,992 -23.26 87 -50.57 0.0000
2022-11-10 2022-09-30 13F AC IMMUNE SHS H00263105 55,866 1,041 1.90 176 -11.11 0.0001
2022-08-10 2022-06-30 13F AC IMMUNE SHS H00263105 54,825 36,000 191.24 198 164.00 0.0001
2022-05-16 2022-03-31 13F AC IMMUNE SHS H00263105 18,825 -73,669 -79.65 75 -83.59 0.0000
2022-02-14 2021-12-31 13F AC IMMUNE SHS H00263105 92,494 71,179 333.94 457 219.58 0.0001
2021-11-15 2021-09-30 13F AC IMMUNE SHS H00263105 21,315 20,162 1,748.66 143 1,330.00 0.0000
2021-08-13 2021-06-30 13F AC IMMUNE SHS H00263105 1,153 328 39.76 10 66.67 0.0000
2021-05-12 2021-03-31 13F AC IMMUNE SHS H00263105 825 -3,197 -79.49 6 -71.43 0.0000
2021-02-11 2020-12-31 13F AC IMMUNE SHS H00263105 4,022 3,197 387.52 21 425.00 0.0000
2020-11-12 2020-09-30 13F AC IMMUNE SHS H00263105 825 -2,000 -70.80 4 -78.95 0.0000
2020-07-31 2020-06-30 13F AC IMMUNE SHS H00263105 2,825 2,000 242.42 19 216.67 0.0000
2020-05-01 2020-03-31 13F AC IMMUNE SHS H00263105 825 -1,080 -56.69 6 -62.50 0.0000
2020-02-14 2019-12-31 13F AC IMMUNE SHS H00263105 1,905 672 54.50 16 166.67 0.0000
2019-11-14 2019-09-30 13F AC IMMUNE SHS H00263105 1,233 -2,532 -67.25 6 -71.43 0.0000
2019-08-14 2019-06-30 13F AC IMMUNE SHS H00263105 3,765 -343 -8.35 21 0.00 0.0000
2019-05-14 2019-03-31 13F AC IMMUNE SHS H00263105 4,108 3,283 397.94 21 162.50 0.0000
2019-02-14 2018-12-31 13F AC IMMUNE SHS H00263105 825 -1,694 -67.25 8 -61.90 0.0000
2018-11-14 2018-09-30 13F AC IMMUNE SHS H00263105 2,519 2,519 21 0.0000
2018-08-14 2018-06-30 13F AC IMMUNE SHS H00263105 0 -2,119 -100.00 0 -100.00
2018-05-15 2018-03-31 13F AC IMMUNE SHS H00263105 2,119 2,057 3,317.74 22 2,100.00 0.0000
2018-02-14 2017-12-31 13F AC IMMUNE SHS H00263105 62 62 1 0.0000
2017-11-14 2017-09-30 13F AC IMMUNE SHS H00263105 0 -1,157 -100.00 0 -100.00
2017-11-14 2017-06-30 13F/A-1 AC IMMUNE SHS H00263105 1,157 1,157 10 0.0000
2017-08-14 2017-06-30 13F AC IMMUNE SHS H00263105 1,157 1,157 10
2017-02-14 2016-12-31 13F AC IMMUNE SHS H00263105 0 -1,537 -100.00 0 -100.00
2016-11-14 2016-09-30 13F AC IMMUNE SHS H00263105 1,537 1,537 25 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.